Carisma Therapeutics Inc

Aprea Therapeutics, Inc is a biopharmaceutical company based in Doylestown, PA that is dedicated to revolutionizing cancer treatment through their pioneering approach to synthetic lethality and precision oncology. With a diversified portfolio of clinical and pre-clinical assets, Aprea Therapeutics develops highly selective DDR-targeted therapeutics that aim to address the unmet medical needs of cancer patients with mutations in DNA damage response genes, while maximizing efficacy and minimizing toxicity.Generated from the website

Neurokappa Therapeutics LLC is a Philadelphia-based company comprised of a team of scientists and business professionals dedicated to developing innovative medications for neurological diseases such as stroke, pain, and addiction. Leveraging their deep understanding of opioid receptors, they aim to create novel compounds that target these receptors, with potential therapeutic applications in stroke therapy, pain management, depression, and addiction therapy. The company's vision is to provide an effective alternative pathway for delivering medications for neurological diseases, particularly in out-of-hospital settings where intravenous access may not be readily available. With a focus on prioritizing the efficacy of action over the mechanism of actions, Neurokappa Therapeutics LLC is committed to continuously pursuing both scientific discoveries and the development of new indications for existing medications.Generated from the website

Enterin, Inc is a pioneering pharmaceutical company based in Philadelphia, PA, with a groundbreaking mission to develop a revolutionary drug that repairs the dysfunctional gut-brain axis in patients suffering from neurodegenerative diseases. Their lead molecule, ENT-01, has shown promising results in preclinical models of Parkinson's Disease by displacing -synuclein aggregates and restoring normal signaling between the gut and the brain. With recent success in meeting its primary endpoint in a Phase 2b study for Parkinson's Disease patients, Enterin's clinical data suggests that repairing the gut-brain axis can significantly enhance the quality of life for individuals affected by Parkinson's Disease and other neurodegenerative conditions, by addressing multiple non-motor symptoms. Driven by a vision of providing new hope against Parkinson's, autism, and other neurodegenerative diseases, Enterin is at the forefront of scientific research and development in this field.Generated from the website